KIAA1524 ELISA Kit (Human)

Intra-assay Precision (Precision within an assay) : 3 samples with low, middle and high level Cancerous Inhibitor Of PP2A (CIP2A) were tested 20 times on one plate, respectively. Inter-assay Precision (Precision between assays) : 3 samples with low, middle and high level Cancerous Inhibitor Of PP2A (CIP2A) were tested on 3 different plates, 8 replicates in each plate. CV (%) = SD/meanX100 Intra-Assay: CV<10% Inter-Assay: CV<12%

Cancerous inhibitor of PP2A; cancerous inhibitor of protein phosphatase 2A; cell proliferation regulating inhibitor of protein phosphatase 2A; KIAA1524; NOCIVA; p90; p90 autoantigen; protein CIP2A.

The test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Cancerous Inhibitor Of PP2A (CIP2A) . Standards or samples are then added to the appropriate microtiter plate wells with a biotin-conjugated antibody specific to Cancerous Inhibitor Of PP2A (CIP2A) . Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Cancerous Inhibitor Of PP2A (CIP2A), biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm +/- 10nm. The concentration of Cancerous Inhibitor Of PP2A (CIP2A) in the samples is then determined by comparing the O.D. of the samples to the standard curve.

Reconstitution & Storage Instructions Western Blotting/Immunoblotting (WB/IB) Protocol Immunohistochemistry (IHC) Protocol Immunocytochemistry (ICC) Protocol Enzyme-Linked ImmunoSorbent Assay (ELISA) Protocol Blocking Peptide Competition Protocol (BPCP) Immunoprecipitation (IP) Protocol Antibody Array (AA) Protocol Reconstitution & Storage Instructions Reconstitution & Storage Instructions Western Blotting/Immunoblotting (WB/IB) Protocol Western Blotting/Immunoblotting (WB/IB) Protocol Immunohistochemistry (IHC) Protocol Immunohistochemistry (IHC) Protocol Immunocytochemistry (ICC) Protocol Immunocytochemistry (ICC) Protocol Enzyme-Linked ImmunoSorbent Assay (ELISA) Protocol Enzyme-Linked ImmunoSorbent Assay (ELISA) Protocol Blocking Peptide Competition Protocol (BPCP) Blocking Peptide Competition Protocol (BPCP) Immunoprecipitation (IP) Protocol Immunoprecipitation (IP) Protocol Antibody Array (AA) Protocol Antibody Array (AA) Protocol

Matrix Recovery Range (%) Average (%) serum (n=5) 98-105 101 EDTA plasma (n=5) 92-101 96 heparin plasma (n=5) 84-92 87 Matrix Recovery Range (%) Average (%) Matrix Recovery Range (%) Average (%) serum (n=5) 98-105 101 serum (n=5) 98-105 101 EDTA plasma (n=5) 92-101 96 EDTA plasma (n=5) 92-101 96 heparin plasma (n=5) 84-92 87 heparin plasma (n=5) 84-92 87

Component Amount Anti-KIAA1524 Microplate 96 Wells (12 x 8 Well Strips) KIAA1524 Lyophilized Standard 2 x 10 ng 100X Biotinylated KIAA1524 Detector Antibody 120 uL Avidin/HRP Conjugate 120 uL Standard Diluent 1 x 20 mL Detector Antibody Diluent 1 x 12 mL Conjugate Diluent 1 x 12 mL 30X Wash Buffer 1 x 20 mL TMB Substrate 1 x 9 mL Stop Solution 1 x 6 mL Component Amount Component Amount Anti-KIAA1524 Microplate 96 Wells (12 x 8 Well Strips) Anti-KIAA1524 Microplate 96 Wells (12 x 8 Well Strips) KIAA1524 Lyophilized Standard 2 x 10 ng KIAA1524 Lyophilized Standard 2 x 10 ng 100X Biotinylated KIAA1524 Detector Antibody 120 uL 100X Biotinylated KIAA1524 Detector Antibody 120 uL Avidin/HRP Conjugate 120 uL Avidin/HRP Conjugate 120 uL Standard Diluent 1 x 20 mL Standard Diluent 1 x 20 mL Detector Antibody Diluent 1 x 12 mL Detector Antibody Diluent 1 x 12 mL Conjugate Diluent 1 x 12 mL Conjugate Diluent 1 x 12 mL 30X Wash Buffer 1 x 20 mL 30X Wash Buffer 1 x 20 mL TMB Substrate 1 x 9 mL TMB Substrate 1 x 9 mL Stop Solution 1 x 6 mL Stop Solution 1 x 6 mL

This assay has high sensitivity and excellent specificity for detection of Cancerous Inhibitor Of PP2A (CIP2A) . No significant cross-reactivity or interference between Cancerous Inhibitor Of PP2A (CIP2A) and analogues was observed.